Last reviewed · How we verify
NCT06258083: SINCERE
Systemic Right Ventricle Long-term Outcome
trial in Transposition of the Great Arteries in 542 participants. Completed in 24 August 2023.
24 August 2023
Quick facts
| Lead sponsor | University Medical Center Groningen |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 542 |
| Start date | 26 August 2022 |
| Primary completion | 24 August 2023 |
| Estimated completion | 24 August 2023 |
| Sites | 9 locations across Belgium, Netherlands |
Conditions studied
- Transposition of the Great Arteries — all drugs for Transposition of the Great Arteries →
- Systemic Right Ventricle — all drugs for Systemic Right Ventricle →
Sponsor
University Medical Center Groningen
Who can join
12 and older, any sex, with Transposition of the Great Arteries or Systemic Right Ventricle. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Patients with the transposition of great arteries (TGA) who undergo atrial switch operation and congenitally corrected TGA (ccTGA) patients have the right ventricle as their systemic ventricle. Function of the systemic right ventricle (SRV) could deteriorate which is associated with impaired prognosis. It is of paramount importance to understand the course and fate of these patients during a long-term follow-up to identify the determinants of adverse outcomes.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Heart failure in patients with a systemic right ventricle: A multicentre study with long-term follow-up.
Ansari Ramandi MM, Budts W, Roos-Hesselink JW, Helbing WA, et al · · 2025 · PMID 40279105 · DOI 10.1002/ejhf.3664
Verify or expand the search:
- PubMed search for NCT06258083
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Transposition of the Great Arteries
Currently open trials in the same condition.
- NCT06932081 — Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry · recruiting
- NCT06768008 — An Integrated Prenatal and Postnatal Treatment Model for the Treatment of Newborns With Critical Congenital Heart Diseas · recruiting
Other University Medical Center Groningen trials
Trials by the same sponsor.
- NCT06647602 — Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy · not yet recruiting
- NCT06809946 — Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy · Phase 2 · not yet recruiting
- NCT07527390 — CANagliflozin In DIALysis Patients · Phase 4 · not yet recruiting
- NCT07439237 — Implant-supported Maxillary Overdentures; a 15-years Evaluation · not yet recruiting
- NCT07275437 — Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With Reduced Ejection Fra · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06258083 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Medical Center Groningen
- Last refreshed: 14 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06258083.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing